FindTrial
Sign In

medroxyprogesterone

DRUG16 trials

Sponsors

Rheinische Friedrich-Wilhelms-Universitaet Bonn, Merck Sharp & Dohme LLC, National Heart, Lung, and Blood Institute (NHLBI), SWOG Cancer Research Network, Gynecologic Oncology Group

Conditions

Alzheimer DiseaseBone DiseasesBreast CancerBreast cancerCardiovascular DiseaseCardiovascular DiseasesCognitive ImpairmentCoronary Arteriosclerosis

Phase 2

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
CompletedNCT00033358
National Cancer Institute (NCI)Endometrial Cancer
Start: 2002-02-28Updated: 2013-05-03
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
TerminatedNCT00003179
Gynecologic Oncology GroupEndometrial Cancer
Start: 1998-11-30Target: 360Updated: 2013-06-10
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
CompletedNCT00064025
Gynecologic Oncology GroupEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation +5
Start: 2004-04-30Updated: 2016-04-11
Alzheimer's Disease: Therapeutic Potential of Estrogen
CompletedNCT00066157
University of Wisconsin, MadisonAlzheimer Disease
Start: 2001-09-30End: 2007-12-31Updated: 2018-08-23
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
RecruitingCTIS2024-519563-18-00
Merck Sharp & Dohme LLCBreast cancer, Endometrial cancer, Ovarian cancer
Start: 2025-09-02Target: 22Updated: 2025-10-14

Phase 3

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)
CompletedNCT00000559
National Heart, Lung, and Blood Institute (NHLBI)Cardiovascular Diseases, Coronary Disease, Heart Diseases +2
Start: 1995-03-31End: 2001-08-31Updated: 2016-07-12
Postmenopausal Estrogen/Progestin Interventions (PEPI)
CompletedNCT00000466
National Heart, Lung, and Blood Institute (NHLBI)Bone Diseases, Cardiovascular Diseases, Coronary Disease +8
Start: 1987-09-30End: 2000-10-31Updated: 2016-05-13
Estrogen and Graft Atherosclerosis Research Trial (EAGER)
CompletedNCT00000605
National Heart, Lung, and Blood Institute (NHLBI)Cardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease +3
Start: 1996-08-31End: 2002-07-31Updated: 2016-02-18
Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
CompletedNCT00004650
National Institute of Dental and Craniofacial Research (NIDCR)Osteoporosis
Start: 1993-08-31Target: 150Updated: 2005-06-24
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
CompletedNCT00002920
SWOG Cancer Research NetworkBreast Cancer, Endometrial Cancer
Start: 1997-03-31End: 2009-12-31Updated: 2012-10-31
Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
CompletedNCT00030914
Alliance for Clinical Trials in OncologyHot Flashes
Start: 2002-04-30End: 2006-09-30Updated: 2016-07-13
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
CompletedNCT00026286
Eastern Cooperative Oncology GroupBreast Cancer, Hot Flashes, Menopausal Symptoms
Start: 2000-11-28End: 2007-06-15Updated: 2023-06-15
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
CompletedNCT00416429
Centre Leon BerardKidney Cancer
End: 2005-02-28Target: 456Updated: 2012-09-26

Phase 4

A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS)
RecruitingCTIS2024-515982-32-00
Rheinische Friedrich-Wilhelms-Universitaet BonnOverweight or Obesity, Polycystic Ovary Syndrome (PCOS)
Start: 2025-12-09Target: 198Updated: 2025-10-06

Unknown Phase

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus
CompletedNCT00006133
National Center for Research Resources (NCRR)Systemic Lupus Erythematosus
Start: 2000-06-30Target: 970Updated: 2005-06-24
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
CompletedNCT02122198
University of Colorado, DenverCardiovascular Disease, Cognitive Impairment, Endothelial Dysfunction +1
Start: 2014-09-08End: 2017-09-15Updated: 2022-01-10

Related Papers

Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.
Journal of Clinical Oncology2016-05-20